Web Results

en.wikipedia.org/wiki/Butriptyline

Butriptyline, sold under the brand name Evadyne among others, is a tricyclic antidepressant (TCA) that has been used in the United Kingdom and several other European countries for the treatment of depression but appears to no longer be marketed. Along with trimipramine, iprindole, and amoxapine, it has been described ...

www.sec.gov/news/press-release/2012-2012-237htm

Nov 20, 2012 ... The SEC alleges that Mathew Martoma illegally obtained confidential details about the clinical trial from Dr. Sidney Gilman, who served as chairman of the safety monitoring committee overseeing the trial. Dr. Gilman was selected by Elan Corporation and Wyeth to present the final drug trial results to the ...

www.newyorker.com/magazine/2014/10/13/empire-edge

Oct 13, 2014 ... By the time Gilman made his presentation, however, S.A.C. Capital no longer owned any stock in Elan or Wyeth. In the eight days preceding the conference, Cohen had liquidated his seven-hundred-million-dollar position in the two companies, and had then proceeded to “short” the stocks—to bet against ...

scholarship.law.umn.edu/cgi/viewcontent.cgi?article=1405&context=mjlst

the patient s prescription dispensed a brand-name medication or, instead, its generic equivalent. Wyeth v. Levine (2009) established that such claims may go forward in other words, they are not preempted by federal law if the ...... Strayhorn panel, Judge Gillman observed that the court felt compelled . . . [by the] controlling ...

www.justice.gov/usao-sdny/pr/sac-capital-portfolio-manager-mathew-martoma-found-guilty-manhattan-federal-court

Feb 6, 2014 ... Elan and Wyeth planned to release the full results of the Drug Trial to the investing public at the International Conference on Alzheimer Disease (the “ICAD Presentation”) on July 29, 2008. Dr. Gilman was selected to present the results on behalf companies and was “unblinded” to the full safety and efficacy ...

law.justia.com/cases/nevada/supreme-court/2015/61775.html

Appellants' vehicle was rear-ended by a semitrailer truck driven and owned by Respondents. Appellants sued, and the jury rendered a verdict in Respondents' favor. The district court denied Appellants' motion for a new trial and awarded Respondents attorney fees and costs. The Supreme Court (1) affirmed the judgment ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC2676993

Members of the MSA-C group were Nicholas W. Wood (Chair), Alexandra Dürr, Thomas Klockgether, and Sid Gilman. ..... S.G. serves as Chair of the Safety Monitoring Committee (SMC) for the Elan and Wyeth trials of immunotherapy for Alzheimer disease and of the SMC for the Elan and Transition trials of scyllo- inositol for ...

www.workplacefairness.org/court-decisions-digest

Vega-Colon v. Wyeth Pharm. (No. 09-1861). Decision Date: October 28, 2010. In plaintiff\'s suit against his employer, claiming that the employer discriminated and ..... Gilman v. Marsh & McLennan Cos., Inc. (15-0603). Decision Date: June 16, 2016. In an employment action in which two employee-plaintiffs, under threat of ...

scholarship.law.stjohns.edu/cgi/viewcontent.cgi?article=1570&context=lawreview

Mar 2, 2012 ... "9 See, e.g., Martin v. Wyeth, 96 F. Supp. 689, 695-96 (D. Md.) (holding veteri- nary process patent invalid), affd, 193 F.2d 58 (4th Cir. 1951); Morton v. ...... 218 Gillman v. Stem, 114 F.2d 28, 31 (2d Cir. 1940). 219 Del Mar Eng'g Lab. v. United States, 524 F.2d 1178, 1185 (Ct. Cl. 1975). 220 TP Lab., Inc. v.